Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
<< vorige   
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
           Alle artikelen van de bijbehorende aflevering
                                       Details van artikel 7 van 7 gevonden artikelen
 
 
  The Identification of Factors Linked to the Potential Acceptance of Transgenic Biopharmaceuticals
 
 
Titel: The Identification of Factors Linked to the Potential Acceptance of Transgenic Biopharmaceuticals
Auteur: Duguay, Francois
Katsanis, Lea Prevel
Thakor, Mrugank V.
Verschenen in: Health marketing quarterly
Paginering: Jaargang 21 (2004) nr. 1-2 pagina's 65-89
Jaar: 2004-07-14
Inhoud: In this exploratory study, Rogers' diffusion of innovation theory was used to identify which factors are likely to contribute to the potential acceptance of transgenic biopharmaceuticals (TG-Bs). These products are not yet available to the general public. A scale was designed to assess three of five core attributes related to the potential adoption rate of innovations (Rogers 1995), as well as to measure potential acceptance characteristics for biotechnology products. These attributes were relative advantage, compatibility with existing values, and complexity. In addition, two other characteristics were included: knowledge (Gartrell and Gartrell 1979) and perceived risks (Bauer 1960). The survey was completed by 74 consumers (78% response rate) using convenience sampling. The research findings show that Rogers' three core attributes are supported, but that knowledge and perceived risks were excluded from the model. The model for transgenic biopharmaceuticals consists of: 1. Consumer-related benefits (positively correlated to potential adoption). 2. New types of animals (negatively correlated to potential adoption). 2. New types of animals (negatively correlated to potential adoption). All the scaled items developed for this study were highly significant, which indicates that they can be used successfully by other researchers working in this field. As TG-Bs are a discontinuous innovation, biotechnology companies may need to present the benefits of these products, as well as the ease of their use prior to their launch, in order to increase their potential acceptance by consumers.
Uitgever: Routledge
Bronbestand: Elektronische Wetenschappelijke Tijdschriften
 
 

                             Details van artikel 7 van 7 gevonden artikelen
 
<< vorige   
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland